1. Geburtshilfe Frauenheilkd. 2022 Jun 3;82(6):580-589. doi: 10.1055/a-1811-6106.
 eCollection 2022 Jun.

Update Breast Cancer 2022 Part 1 - Early Stage Breast Cancer.

Welslau M(1), Müller V(2), Lüftner D(3), Schütz F(4), Stickeler E(5), Fasching 
PA(6), Janni W(7), Thomssen C(8), Witzel I(2), Fehm TN(9), Belleville E(10), 
Bader S(6), Seitz K(6), Untch M(11), Thill M(12), Tesch H(13), Ditsch N(14), Lux 
MP(15), Aktas B(16), Banys-Paluchowski M(17), Schneeweiss A(18), Harbeck N(19), 
Würstlein R(19), Hartkopf AD(7), Wöckel A(20), Seliger B(21), Massa C(21), 
Kolberg HC(22).

Author information:
(1)Onkologie Aschaffenburg, Aschaffenburg, Germany.
(2)Department of Gynecology, Hamburg-Eppendorf University Medical Center, 
Hamburg, Germany.
(3)Charité University Hospital, Department of Hematology, Oncology and Tumour 
Immunology, University Medicine Berlin, Berlin, Germany.
(4)Gynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus Speyer, 
Speyer, Germany.
(5)Department of Gynecology and Obstetrics, RWTH University Hospital Aachen, 
Aachen, Germany.
(6)Erlangen University Hospital, Department of Gynecology and Obstetrics, 
Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University 
Erlangen-Nuremberg, Erlangen, Germany.
(7)Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, 
Germany.
(8)Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle 
(Saale), Germany.
(9)Department of Gynecology and Obstetrics, University Hospital Düsseldorf, 
Düsseldorf, Germany.
(10)ClinSol GmbH & Co KG, Würzburg, Germany.
(11)Clinic for Gynecology and Obstetrics, Breast Cancer Center, Genecologic 
Oncology Center, Helios Klinikum Berlin Buch, Berlin, Germany.
(12)Agaplesion Markus Krankenhaus, Department of Gynecology and Gynecological 
Oncology, Frankfurt am Main.
(13)Oncology Practice at Bethanien Hospital, Frankfurt am Main, Germany.
(14)Department of Gynecology and Obstetrics, University Hospital Augsburg, 
Augsburg, Germany.
(15)Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, 
St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Germany.
(16)Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Leipzig, 
Leipzig, Germany.
(17)Department of Gynecology and Obstetrics, University Hospital 
Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
(18)National Center for Tumor Diseases (NCT), Heidelberg University Hospital and 
German Cancer Research Center, Heidelberg, Germany.
(19)Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, 
LMU University Hospital, Munich, Germany.
(20)Department of Gynecology and Obstetrics, University Hospital Würzburg, 
Würzburg, Germany.
(21)Martin-Luther-Universitat Halle-Wittenberg, Institute of Medical Immunology, 
Halle (Saale), Germany.
(22)Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, 
Germany.

Evidence relating to the treatment of breast cancer patients with early-stage 
disease has increased significantly in the past year. Abemaciclib, olaparib, and 
pembrolizumab are new drugs with good efficacy in the relevant patient groups. 
However, some questions remain unanswered. In particular, it remains unclear 
which premenopausal patients with hormone receptor-positive breast cancer should 
be spared unnecessary treatment. The question of the degree to which 
chemotherapy exerts a direct cytotoxic effect on the tumor or reduces ovarian 
function through chemotherapy could be of key importance. This group of patients 
could potentially be spared chemotherapy. New, previously experimental biomarker 
analysis methods, such as spatial analysis of gene expression (spatial 
transcriptomics) are gradually finding their way into large randomized phase III 
trials, such as the NeoTRIP trial. This in turn leads to a better understanding 
of the predictive factors of new therapies, for example immunotherapy. This 
review summarizes the scientific innovations from recent congresses such as the 
San Antonio Breast Cancer Symposium 2021 but also from recent publications.

The Author(s). This is an open access article published by Thieme under the 
terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, 
permitting copying and reproduction so long as the original work is given 
appropriate credit. Contents may not be used for commecial purposes, or adapted, 
remixed, transformed or built upon. ( 
https://creativecommons.org/licenses/by-nc-nd/4.0/ ).

DOI: 10.1055/a-1811-6106
PMCID: PMC9315400
PMID: 35903719

Conflict of interest statement: Conflict of Interest/Interessenkonflikt B. A. 
received honoria and travel grants from AstraZeneca, Gilead, Genomic Health, 
Roche, Novartis, Celgene, Lilly, MSD, Eisai, Teva, Tesaro, Daiichi Sankyo and 
Pfizer. M. B.-P. received honoria for lectures and advisory role from 
AstraZeneca, Gilead, Roche, Novartis, Eli Lilly, MSD, Eisai, pfm, Amgen, Seagen, 
Daiichi-Sankyo and Pfizer, and study support from Mammotome, Endomag and Merit 
Medical. E. B. received honoraria from Novartis, Hexal, BMS, Lilly, Pfizer, 
Roche, MSD, BBraun and onkowissen.de for consulting, clinical research 
management or medical education activities. S. B. has no conflict of interest. 
N. D. has received honoraria from MSD, Roche, AstraZeneca, Teva, Pfizer, 
Novartis, Seagen,Gilead, MCI Healthcare. P. A. F. reports personal fees from 
Novartis, grants from Biontech, personal fees from Pfizer, personal fees from 
Daiichi Sankyo, personal fees from AstraZeneca, personal fees from Eisai, 
personal fees from Merck Sharp & Dohme, grants from Cepheid, personal fees from 
Lilly, personal fees from Pierre Fabre, personal fees from SeaGen, personal fees 
from Roche, personal fees from Hexal, personal fees from Agendia, personal fees 
from Gilead. T. N. F. has participated on advisory boards for Amgen, Daiichi 
Sankyo, Novartis, Pfizer, and Roche and has received honoraria for lectures from 
Amgen, Celgene, Daiichi Sankyo, Roche, Novartis and Pfizer. A. D. H. received 
speaker and consultancy honoraria from AstraZeneca, Genomic Health, Roche, 
Novartis, Celgene, Lilly, MSD, Eisai, Teva, Tesaro, Daiichi Sankyo, Hexal and 
Pfizer. N. H. received honoraria for lectures and/or consulting from Amgen, 
AstraZeneca, Daiichi Sankyo, Exact Sciences, Gilead, Lilly, MSD, Mylan, 
Novartis, Pierre-Fabre, Pfizer, Roche, Sandoz, Seagen. W. J. has received 
research Grants and/or honoraria from Sanofi-Aventis, Daiichi Sankyo, Novartis, 
Roche, Pfizer, Lilly, AstraZeneca, Chugai, GSK, Eisai, Cellgene and 
Johnson & Johnson. H.-C. K. has received honoraria from Pfizer, Novartis, Roche, 
Genomic Health/Exact Sciences, Amgen, AstraZeneca, Riemser, Carl Zeiss Meditec, 
Teva, Theraclion, Janssen-Cilag, GSK, LIV Pharma, Lily, SurgVision, Onkowissen, 
Gilead, Daiichi Sankyo and MSD, travel support from Carl Zeiss Meditec, LIV 
Pharma, Novartis, Amgen, Pfizer, Daiichi Sankyo, Tesaro and owns stock of 
Theraclion SA and Phaon Scientific GmbH. D. L. received honoraria from Amgen, 
AstraZeneca, Eli Lilly, Gilead, GSK, Loreal, MSD, Novartis, Onkowissen, Pfizer, 
Seagen, Teva. M. P. L. has participated on advisory boards for AstraZeneca, 
Lilly, MSD, Novartis, Pfizer, Eisai, Gilead, Exact Sciences, Pierre Fabre, 
Grünenthal, Daiichi Sankyo, PharmaMar and Roche and has received honoraria for 
lectures from MSD, Lilly, Roche, Novartis, Pfizer, Exact Sciences, Daiichi 
Sankyo, Grünenthal, Gilead, AstraZeneca, and Eisai. He is editorial board member 
of medactuell from medac. V. M. received speaker honoraria from Amgen, 
AstraZeneca, Daiichi Sankyo, Eisai, GSK, Pfizer, MSD, Medac, Novartis, Roche, 
Teva, Seagen, Onkowissen, high5 Oncology, Medscape, Gilead. Consultancy 
honoraria from Hexal, Roche, Pierre Fabre, Amgen, ClinSol, Novartis, MSD, 
Daiichi Sankyo, Eisai, Lilly, Sanofi, Seagen, Gilead. Institutional research 
support from Novartis, Roche, Seagen, Genentech. Travel grants: Roche, Pfizer, 
Daiichi Sankyo. E. S. received honoraria from Roche, Celgene, AstraZeneca, 
Novartis, Pfizer, Tesaro, Aurikamed GmbH, MCI Deutschland GmbH, bsh medical 
communications GmbH, Onkowissen TV. A. S. received research grants from Celgene, 
Roche, honoraria from Amgen, AstraZeneca, Aurikamed, Bayer, Celgene, Clinsol, 
Connectmedica, Gilead, GSK, I-MED, Lilly, MCI Deutschland, Metaplan, MSD, 
Nanostring, Novartis, Onkowissen.de, Promedicis, Pfizer, Pierre Fabre, Roche, 
Seagen, Streamedup, Teva, Tesaro, Thieme and travel support from Celgene, 
Pfizer, Roche. F. S. participated on advisory boards for Novartis, Lilly, Amgen 
and Roche and received honoraria for lectures from Roche, AstraZeneca, MSD, 
Novartis and Pfizer. K. S. has no conflict of interest. H. T. received honoraria 
from Novartis, Roche, Celgene, Teva, Pfizer, AstraZeneca and travel support from 
Roche, Celgene and Pfizer. C. T. received honoraria for advisory boards and 
lectures from Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Gilead, Lilly, 
MSD, Mylan, Nanostring, Novartis, Pfizer, Pierre Fabre, Puma, Roche, Seagen, 
Vifor. M. T. has participated on advisory boards for AstraZeneca, Clovis, 
Daiichi Sanyo, Eisai, Gilead Science, GSK, Lilly, MSD, Novartis, Organon, 
Pfizer, Exact Sciences, Pierre-Fabre, Seagen and Roche and has received 
honoraria for lectures from Amgen, Clovis, Daiichi Sankyo, Eisai, GSK, Lilly, 
MSD, Roche, Novartis, Organon, Pfizer, Seagen, Exact Sciences, Viatris, Vifor 
and AstraZeneca and has received trial funding by Exact Sciences and Endomag 
Manuscript support was done by Amgen, ClearCut, pfm medical, Roche, Servier, 
Vifor. M. U. all honoraria went to the institution/employer: Abbvie, Amgen, 
AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Lilly, MSD Merck, Mundipharma, 
Myriad Genetics, Pfizer, PUMA Biotechnology, Roche, Sanofi Aventis, Novartis, 
Pierre Fabre. M. W. has participated on advisory boards for AstraZeneca, Lilly, 
MSD, Novartis, Pfizer and Roche. I. W. has participated on advisory boards for 
Novartis, Daichii Sankyo, Lilly, Pfizer and received speaker honoraria from 
Astra Zeneca, Daichii Sankyo, MSD, Novartis, Pfizer, Roche. A. W. participated 
on advisory boards for Novartis, Lilly, Amgen, Pfizer, Roche, Tesaro, Eisai and 
received honoraria for lectures from Novartis, Pfizer, Aurikamed, Roche, 
Celgene. R. W. has received honoraria, travel support from Agendia, Amgen, 
Aristo, AstraZeneca, Boehringer Ingelheim, Carl Zeiss, Celgene, Daiichi Sankyo, 
Eisai, Exact Sciences, Genomic Health, Gilead, GlaxoSmithKline, Hexal, Lilly, 
Medstrom Medical, MSD, Mundipharma, Mylan, Nanostring, Novartis, Odonate, 
Paxman, Palleos, Pfizer, Pierre Fabre, PumaBiotechnology, Riemser, Roche, 
Sandoz/Hexal, Sanofi Genzyme, Seattle Genetics/Seagen, Tesaro Bio, Teva, 
Veracyte, Viatris./ B. A. hat von AstraZeneca, Gilead, Genomic Health, Roche, 
Novartis, Celgene, Lilly, MSD, Eisai, Teva, Tesaro, Daiichi Sankyo und Pfizer 
Honorare und Reisekostenzuschüsse erhalten. M. B.-P. hat von AstraZeneca, 
Gilead, Roche, Novartis, Eli Lilly, MSD, Eisai, pfm, Amgen, Seagen, Daiichi 
Sankyo und Pfizer Honorare für Vorlesungen und die Ausübung einer beratenden 
Funktion sowie von Mammotome, Endomag und Merit Medical Studienbeihilfen 
erhalten. E. B. hat von Novartis, Hexal, BMS, Lilly, Pfizer, Roche, MSD, BBraun 
und onkowissen.de für Beratung, klinisches Forschungsmanagement oder 
medizinische Aus- und Weiterbildung Honorare erhalten. S. B. hat keinen 
Interessenkonflikt. N. D. hat von MSD, Roche, AstraZeneca, Teva, Pfizer, 
Novartis, Seagen, Gilead und MCI Healthcare Honorare erhalten. P. A. F. weist 
Folgendes aus: Honorare von Novartis, Zuwendungen von Biontech, Honorare von 
Pfizer, Honorare von Daiichi Sankyo, Honorare von AstraZeneca, Honorare von 
Eisai, Honorare von Merck Sharp & Dohme, Zuwendungen von Cepheid, Honorare von 
Lilly, Honorare von Pierre Fabre, Honorare von SeaGen, Honorare von Roche, 
Honorare von Hexal, Honorare von Agendia und Honorare von Gilead. T. N. F. hat 
in beratenden Gremien bei Amgen, Daiichi Sankyo, Novartis, Pfizer und Roche 
mitgewirkt und von Amgen, Celgene, Daiichi Sankyo, Roche, Novartis und Pfizer 
Honorare für Vorlesungen erhalten. A. D. H. hat als Referent und Berater von 
AstraZeneca, Genomic Health, Roche, Novartis, Celgene, Lilly, MSD, Eisai, Teva, 
Tesaro, Daiichi Sankyo, Hexal und Pfizer Honorare erhalten. N. H. hat für 
Vorlesungen und/oder Beratung von Amgen, AstraZeneca, Daiichi Sankyo, Exact 
Sciences, Gilead, Lilly, MSD, Mylan, Novartis, Pierre-Fabre, Pfizer, Roche, 
Sandoz und Seagen Honorare erhalten. W. J. hat von Sanofi-Aventis, Daiichi 
Sankyo, Novartis, Roche, Pfizer, Lilly, AstraZeneca, Chugai, GSK, Eisai, 
Cellgene und Johnson & Johnson Forschungsbeihilfen und/oder Honorare erhalten. 
H.-C. K. hat von Pfizer, Novartis, Roche, Genomic Health/Exact Sciences, Amgen, 
AstraZeneca, Riemser, Carl Zeiss Meditec, Teva, Theraclion, Janssen-Cilag, GSK, 
LIV Pharma, Lily, SurgVision, Onkowissen, Gilead, Daiichi Sankyo und MSD 
Honorare sowie von Carl Zeiss Meditec, LIV Pharma, Novartis, Amgen, Pfizer, 
Daiichi Sankyo und Tesaro Reisekostenzuschüsse erhalten und besitzt Aktien von 
Theraclion SA und Phaon Scientific GmbH. D. L. hat von Amgen, AstraZeneca, Eli 
Lilly, Gilead, GSK, Loreal, MSD, Novartis, Onkowissen, Pfizer, Seagen und Teva 
Honorare erhalten. M. P. L. hat in beratenden Gremien bei AstraZeneca, Lilly, 
MSD, Novartis, Pfizer, Eisai, Gilead, Exact Sciences, Pierre Fabre, Grünenthal, 
Daiichi Sankyo, PharmaMar und Roche mitgewirkt und von MSD, Lilly, Roche, 
Novartis, Pfizer, Exact Sciences, Daiichi Sankyo, Grünenthal, Gilead, 
AstraZeneca und Eisai Honorare für Vorlesungen erhalten. Er ist Mitglied der 
Redaktion von medactuell von medac. V. M. hat von Amgen, AstraZeneca, Daiichi 
Sankyo, Eisai, GSK, Pfizer, MSD, Medac, Novartis, Roche, Teva, Seagen, 
Onkowissen, high5 Oncology, Medscape und Gilead Honorare als Referent erhalten. 
Beraterhonorare von Hexal, Roche, Pierre Fabre, Amgen, ClinSol, Novartis, MSD, 
Daiichi Sankyo, Eisai, Lilly, Sanofi, Seagen, Gilead. Institutionelle 
Forschungsunterstützung von Novartis, Roche, Seagen, Genentech. 
Reisekostenzuschüsse von: Roche, Pfizer, Daiichi Sankyo. E. S. hat von Roche, 
Celgene, AstraZeneca, Novartis, Pfizer, Tesaro, Aurikamed GmbH, MCI Deutschland 
GmbH, bsh medical communications GmbH und Onkowissen TV-Honorare erhalten. A. S. 
hat von Celgene und Roche Forschungszuschüsse, von Amgen, AstraZeneca, 
Aurikamed, Bayer, Celgene, Clinsol, Connectmedica, Gilead, GSK, I-MED, Lilly, 
MCI Deutschland, Metaplan, MSD, Nanostring, Novartis, Onkowissen.de, Promedicis, 
Pfizer, Pierre Fabre, Roche, Seagen, Streamedup, Teva, Tesaro und Thieme 
Honorare sowie von Celgene, Pfizer und Roche Reisekostenzuschüsse erhalten. 
F. S. hat in beratenden Gremien bei Novartis, Lilly, Amgen und Roche mitgewirkt 
und von Roche, AstraZeneca, MSD, Novartis und Pfizer Honorare für Vorlesungen 
erhalten. K. S. hat keinen Interessenkonflikt. H. T. hat von Novartis, Roche, 
Celgene, Teva, Pfizer und AstraZeneca Honorare sowie von Roche, Celgene und 
Pfizer Reisekostenzuschüsse erhalten. C. T. hat für die Mitwirkung in beratenden 
Gremien und für Vorlesungen von Amgen, AstraZeneca, Celgene, Daiichi Sankyo, 
Eisai, Gilead, Lilly, MSD, Mylan, Nanostring, Novartis, Pfizer, Pierre Fabre, 
Puma, Roche, Seagen und Vifor Honorare erhalten. M. T. hat in beratenden Gremien 
bei AstraZeneca, Clovis, Daiichi Sankyo, Eisai, Gilead Science, GSK, Lilly, MSD, 
Novartis, Organon, Pfizer, Exact Sciences, Pierre-Fabre, Seagen und Roche 
mitgewirkt und von Amgen, Clovis, Daiichi Sankyo, Eisai, GSK, Lilly, MSD, Roche, 
Novartis, Organon, Pfizer, Seagen, Exact Sciences, Viatris, Vifor und 
AstraZeneca Honorare für Vorlesungen sowie von Exact Sciences und Endomag 
finanzielle Mittel für Versuche erhalten. Manuskriptzuschüsse wurden von Amgen, 
ClearCut, pfm medical, Roche, Servier und Vifor geleistet. M. U. Alle Honorare 
gingen an die Institution/den Arbeitgeber: Abbvie, Amgen, AstraZeneca, Celgene, 
Daiichi Sankyo, Eisai, Lilly, MSD Merck, Mundipharma, Myriad Genetics, Pfizer, 
PUMA Biotechnology, Roche, Sanofi Aventis, Novartis, Pierre Fabre. M. W. hat in 
beratenden Gremien bei AstraZeneca, Lilly, MSD, Novartis, Pfizer und Roche 
mitgewirkt. I. W. hat in beratenden Gremien bei Novartis, Daichii Sankyo, Lilly 
und Pfizer mitgewirkt und von AstraZeneca, Daichii Sankyo, MSD, Novartis, Pfizer 
und Roche Honorare als Referent erhalten. A. W. hat in beratenden Gremien bei 
Novartis, Lilly, Amgen, Pfizer, Roche, Tesaro und Eisai mitgewirkt und von 
Novartis, Pfizer, Aurikamed, Roche und Celgene Honorare für Vorlesungen 
erhalten. R. W. hat von Agendia, Amgen, Aristo, AstraZeneca, Boehringer 
Ingelheim, Carl Zeiss, Celgene, Daiichi Sankyo, Eisai, Exact Sciences, Genomic 
Health, Gilead, GlaxoSmithKline, Hexal, Lilly, Medstrom Medical, MSD, 
Mundipharma, Mylan, Nanostring, Novartis, Odonate, Paxman, Palleos, Pfizer, 
Pierre Fabre, PumaBiotechnology, Riemser, Roche, Sandoz/Hexal, Sanofi Genzyme, 
Seattle Genetics/Seagen, Tesaro Bio, Teva, Veracyte und Viatris Honorare und 
Reisekostenzuschüsse erhalten.